benazepril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 299 86541-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benazepril
  • cibacen
  • benazepril hydrochloride
  • benazepril HCl
prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion
  • Molecular weight: 424.50
  • Formula: C24H28N2O5
  • CLOGP: 1.82
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.61
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 78 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.13 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 18 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 25, 1991 FDA US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 141.67 12.87 111 17302 41342 56233312
Cerebrovascular accident 125.46 12.87 154 17259 99116 56175538
Myocardial infarction 112.41 12.87 141 17272 92729 56181925
Coronary artery disease 110.72 12.87 85 17328 30711 56243943
Cardiac failure congestive 102.69 12.87 131 17282 87589 56187065
Off label use 61.94 12.87 49 17364 556131 55718523
Drug ineffective 54.05 12.87 129 17284 918860 55355794
Maternal exposure during pregnancy 43.98 12.87 4 17409 189549 56085105
Transient ischaemic attack 43.82 12.87 53 17360 33524 56241130
Rheumatoid arthritis 43.42 12.87 33 17380 382571 55892083
Contraindicated product administered 43.04 12.87 4 17409 186282 56088372
Chest pain 42.33 12.87 142 17271 189655 56084999
Drug intolerance 39.91 12.87 16 17397 264802 56009852
Dizziness 37.45 12.87 221 17192 375919 55898735
Blood pressure inadequately controlled 37.29 12.87 21 17392 4503 56270151
Treatment failure 36.00 12.87 5 17408 170387 56104267
Swollen tongue 34.98 12.87 45 17368 30279 56244375
Mitral valve incompetence 32.87 12.87 34 17379 18119 56256535
Infusion related reaction 32.50 12.87 12 17401 208919 56065735
Renal failure 32.38 12.87 91 17322 110409 56164245
Systemic lupus erythematosus 32.25 12.87 8 17405 180070 56094584
Vasodilatation 31.32 12.87 15 17398 2306 56272348
Glossodynia 30.99 12.87 5 17408 152453 56122201
Product complaint 30.77 12.87 27 17386 11733 56262921
Carotid artery stenosis 30.53 12.87 19 17394 4891 56269763
Oropharyngeal swelling 30.08 12.87 11 17402 860 56273794
Oedema peripheral 29.60 12.87 118 17295 171136 56103518
Arteriosclerosis 29.46 12.87 24 17389 9429 56265225
Angina unstable 29.38 12.87 21 17392 6800 56267854
Rhabdomyolysis 28.90 12.87 48 17365 40610 56234044
Renal tubular atrophy 27.99 12.87 10 17403 731 56273923
Completed suicide 26.23 12.87 96 17317 133737 56140917
Kounis syndrome 25.82 12.87 11 17402 1287 56273367
Wound 25.17 12.87 6 17407 138798 56135856
Nephrosclerosis 25.11 12.87 10 17403 986 56273668
Emotional distress 25.10 12.87 38 17375 29725 56244929
Cardiac disorder 24.71 12.87 48 17365 45839 56228815
Cardiovascular disorder 24.56 12.87 23 17390 10866 56263788
Exposure during pregnancy 24.51 12.87 6 17407 136336 56138318
Tricuspid valve incompetence 22.52 12.87 24 17389 13229 56261425
Renal injury 22.45 12.87 20 17393 8867 56265787
Hypertension 20.79 12.87 138 17275 244140 56030514
Arteriosclerosis coronary artery 20.58 12.87 18 17395 7787 56266867
Kidney fibrosis 19.75 12.87 10 17403 1732 56272922
Blood pressure increased 19.68 12.87 93 17320 145083 56129571
Dehydration 19.57 12.87 99 17314 158726 56115928
Reaction to excipient 19.49 12.87 9 17404 1275 56273379
Depression 19.28 12.87 108 17305 180009 56094645
Swelling face 19.26 12.87 49 17364 56020 56218634
Injury 19.22 12.87 51 17362 59800 56214854
Pericarditis 19.18 12.87 5 17408 108918 56165736
Gastrooesophageal reflux disease 19.15 12.87 63 17350 83194 56191460
Palpitations 19.10 12.87 71 17342 99601 56175053
Gastrointestinal haemorrhage 18.86 12.87 59 17354 75892 56198762
Fear 18.58 12.87 23 17390 14885 56259769
Hyperdynamic left ventricle 17.60 12.87 5 17408 173 56274481
Joint swelling 17.44 12.87 40 17373 289760 55984894
Coronary artery occlusion 16.81 12.87 16 17397 7713 56266941
Keratoacanthoma 16.70 12.87 6 17407 446 56274208
Vasoplegia syndrome 16.18 12.87 8 17405 1317 56273337
Blood glucose increased 15.64 12.87 55 17358 75096 56199558
Product use issue 15.42 12.87 21 17392 186020 56088634
Therapeutic product effect decreased 15.21 12.87 18 17395 169434 56105220
Tendon rupture 15.20 12.87 15 17398 7555 56267099
C-reactive protein increased 15.07 12.87 3 17410 78681 56195973
Blood urea increased 14.91 12.87 27 17386 24446 56250208
Pyrexia 14.77 12.87 73 17340 418700 55855954
Peripheral vascular disorder 14.69 12.87 13 17400 5712 56268942
Cardiomegaly 13.85 12.87 21 17392 16446 56258208
Rhinitis allergic 13.79 12.87 15 17398 8459 56266195
Laryngeal pain 13.75 12.87 11 17402 4209 56270445
Hyperlipidaemia 13.71 12.87 22 17391 18087 56256567
Hiatus hernia 13.69 12.87 23 17390 19629 56255025
Tubulointerstitial nephritis 13.66 12.87 21 17392 16644 56258010
Anxiety 13.44 12.87 104 17309 193068 56081586
Haemorrhoids 13.22 12.87 23 17390 20183 56254471
Asthenia 13.18 12.87 163 17250 342810 55931844
Muscle spasms 13.15 12.87 80 17333 137291 56137363
Mental status changes 13.11 12.87 33 17380 37468 56237186
Alopecia 12.89 12.87 47 17366 293411 55981243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 198.59 13.07 143 13614 33475 31650112
Myocardial infarction 127.58 13.07 198 13559 113256 31570331
Coronary artery disease 102.98 13.07 113 13644 45974 31637613
Cardiac failure congestive 73.44 13.07 127 13630 79260 31604327
Cerebrovascular accident 69.44 13.07 124 13633 79360 31604227
Off label use 54.21 13.07 43 13714 347231 31336356
Injury 33.43 13.07 42 13715 19667 31663920
Swollen tongue 29.48 13.07 32 13725 12830 31670757
Chest pain 27.53 13.07 112 13645 116845 31566742
Product complaint 26.98 13.07 21 13736 5503 31678084
Emotional distress 26.62 13.07 32 13725 14324 31669263
Blood glucose increased 26.52 13.07 72 13685 61011 31622576
Nodular rash 23.05 13.07 6 13751 104 31683483
Lymphomatoid papulosis 19.50 13.07 6 13751 194 31683393
Asthenia 18.39 13.07 163 13594 224592 31458995
Blood pressure inadequately controlled 18.07 13.07 12 13745 2457 31681130
Neutropenia 17.61 13.07 21 13736 140343 31543244
Pancreatitis 17.39 13.07 44 13713 35727 31647860
Carotid artery stenosis 17.11 13.07 15 13742 4637 31678950
Blood gases abnormal 17.02 13.07 6 13751 299 31683288
Shock 16.82 13.07 33 13724 22612 31660975
Hyperlipidaemia 16.18 13.07 24 13733 13136 31670451
Depression 16.11 13.07 80 13677 90735 31592852
Angina unstable 16.10 13.07 22 13735 11173 31672414
Lip swelling 15.95 13.07 24 13733 13299 31670288
Product use in unapproved indication 15.75 13.07 12 13745 99159 31584428
Acute myocardial infarction 15.55 13.07 53 13704 50770 31632817
Dizziness 15.55 13.07 143 13614 199004 31484583
General physical health deterioration 15.29 13.07 16 13741 113419 31570168
Nephrogenic systemic fibrosis 15.04 13.07 13 13744 3942 31679645
Fear 14.95 13.07 20 13737 9954 31673633
Anxiety 14.62 13.07 78 13679 90955 31592632
Cardiovascular disorder 14.35 13.07 19 13738 9359 31674228
Pharyngeal oedema 14.31 13.07 15 13742 5781 31677806
Transient ischaemic attack 14.30 13.07 32 13725 24024 31659563
Drug interaction 14.14 13.07 45 13712 208498 31475089
Type 2 diabetes mellitus 14.09 13.07 24 13733 14760 31668827
Lacunar infarction 13.98 13.07 11 13746 2929 31680658
Toxicity to various agents 13.88 13.07 37 13720 181450 31502137

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 290.87 12.58 216 24362 66394 70837472
Myocardial infarction 247.74 12.58 301 24277 171344 70732522
Coronary artery disease 229.13 12.58 183 24395 62553 70841313
Cerebrovascular accident 188.30 12.58 240 24338 143230 70760636
Cardiac failure congestive 152.12 12.58 210 24368 135247 70768619
Off label use 99.68 12.58 68 24510 742992 70160874
Transient ischaemic attack 54.16 12.58 73 24505 45871 70857995
Chest pain 52.82 12.58 199 24379 251061 70652805
Emotional distress 49.92 12.58 63 24515 37125 70866741
Angina unstable 48.86 12.58 42 24536 15851 70888015
Rheumatoid arthritis 47.24 12.58 21 24557 291784 70612082
Carotid artery stenosis 43.44 12.58 30 24548 8206 70895660
Product complaint 43.15 12.58 35 24543 12196 70891670
Swollen tongue 42.35 12.58 58 24520 36988 70866878
Cardiac disorder 41.32 12.58 74 24504 59341 70844525
Injury 41.27 12.58 78 24500 65167 70838699
Drug intolerance 38.52 12.58 15 24563 225672 70678194
Blood pressure inadequately controlled 38.35 12.58 24 24554 5568 70898298
Cardiovascular disorder 37.51 12.58 37 24541 16633 70887233
Drug ineffective 34.75 12.58 188 24390 939564 69964302
Drug abuse 34.46 12.58 5 24573 147251 70756615
Renal failure 34.26 12.58 143 24435 188927 70714939
Arteriosclerosis 33.91 12.58 35 24543 16603 70887263
Contraindicated product administered 32.86 12.58 4 24574 134608 70769258
Mitral valve incompetence 32.30 12.58 43 24535 26685 70877181
Depression 30.38 12.58 143 24435 198831 70705035
Dizziness 29.92 12.58 268 24310 463873 70439993
Acute myocardial infarction 29.78 12.58 73 24505 72814 70831052
Hyperlipidaemia 29.78 12.58 39 24539 23824 70880042
Treatment failure 29.23 12.58 7 24571 144135 70759731
Fear 29.11 12.58 36 24542 20775 70883091
Neutropenia 28.77 12.58 28 24550 257128 70646738
Infusion related reaction 27.82 12.58 17 24561 197517 70706349
Arteriosclerosis coronary artery 27.58 12.58 31 24547 16184 70887682
Peripheral vascular disorder 27.26 12.58 22 24556 7610 70896256
Maternal exposure during pregnancy 26.79 12.58 4 24574 115341 70788525
Vasodilatation 25.68 12.58 15 24563 3073 70900793
Blood pressure increased 25.57 12.58 131 24447 188386 70715480
Pyrexia 24.88 12.58 117 24461 606835 70297031
Renal injury 24.40 12.58 29 24549 16065 70887801
Hypertension 23.92 12.58 180 24398 295853 70608013
Blood glucose increased 23.64 12.58 84 24494 102898 70800968
Tricuspid valve incompetence 23.61 12.58 30 24548 17787 70886079
Anxiety 23.18 12.58 143 24435 220187 70683679
Shock 22.72 12.58 46 24532 40379 70863487
Nephrosclerosis 21.66 12.58 11 24567 1710 70902156
Product use in unapproved indication 21.61 12.58 24 24554 207454 70696412
Lacunar infarction 21.58 12.58 17 24561 5679 70898187
Ventricular hypertrophy 21.47 12.58 18 24560 6566 70897300
C-reactive protein increased 21.20 12.58 6 24572 110511 70793355
Exposure during pregnancy 20.46 12.58 3 24575 87714 70816152
Palpitations 20.22 12.58 84 24494 110669 70793197
Completed suicide 19.41 12.58 140 24438 226995 70676871
Laryngeal pain 19.38 12.58 16 24562 5712 70898154
Kounis syndrome 19.36 12.58 13 24565 3398 70900468
Asthenia 19.01 12.58 242 24336 457424 70446442
Anhedonia 18.94 12.58 24 24554 14189 70889677
Coronary artery occlusion 18.77 12.58 24 24554 14321 70889545
Oropharyngeal swelling 18.73 12.58 9 24569 1243 70902623
Systemic lupus erythematosus 18.69 12.58 6 24572 101896 70801970
Renal tubular atrophy 18.68 12.58 10 24568 1732 70902134
Rhabdomyolysis 18.57 12.58 74 24504 95686 70808180
Nodular rash 18.06 12.58 6 24572 314 70903552
Unevaluable event 18.02 12.58 49 24529 52014 70851852
Oedema peripheral 18.02 12.58 138 24440 227953 70675913
Wound 17.78 12.58 6 24572 98726 70805140
Lymphomatoid papulosis 17.67 12.58 6 24572 336 70903530
Cardiomegaly 17.61 12.58 31 24547 24514 70879352
Gastrooesophageal reflux disease 17.45 12.58 70 24508 90769 70813097
Reaction to excipient 17.43 12.58 9 24569 1449 70902417
Pancytopenia 17.42 12.58 16 24562 151091 70752775
Pericarditis 17.39 12.58 4 24574 84701 70819165
Joint swelling 17.17 12.58 39 24539 253172 70650694
Pancreatitis 16.93 12.58 54 24524 62614 70841252
Myocardial ischaemia 16.64 12.58 30 24548 24170 70879696
Gastrointestinal haemorrhage 16.25 12.58 92 24486 137316 70766550
Febrile neutropenia 15.95 12.58 29 24549 204289 70699577
Hypertensive heart disease 15.52 12.58 12 24566 3904 70899962
Gastritis 15.46 12.58 42 24536 44549 70859317
Atrial fibrillation 15.38 12.58 113 24465 184235 70719631
Swelling face 14.90 12.58 52 24526 63112 70840754
Drug interaction 14.74 12.58 75 24503 381366 70522500
Ischaemic cardiomyopathy 14.57 12.58 15 24563 7089 70896777
Product use issue 14.53 12.58 25 24553 179912 70723954
Musculoskeletal stiffness 14.41 12.58 18 24560 147742 70756124
General physical health deterioration 13.94 12.58 39 24539 235992 70667874
Blood urea increased 13.74 12.58 41 24537 45868 70857998
Tendon rupture 13.54 12.58 18 24560 11151 70892715
Electrocardiogram QT prolonged 13.51 12.58 6 24572 83511 70820355
Therapeutic product effect incomplete 13.46 12.58 13 24565 119869 70783997
Cerebral infarction 13.43 12.58 39 24539 42970 70860896
Hyperdynamic left ventricle 13.41 12.58 5 24573 368 70903498
Neck injury 13.10 12.58 9 24569 2441 70901425
Kidney fibrosis 12.83 12.58 10 24568 3290 70900576
Pharyngeal oedema 12.81 12.58 21 24557 15675 70888191
Lip swelling 12.75 12.58 33 24545 34021 70869845

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:50266 Prodrugs
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
FDA PE N0000178477 Decreased Blood Pressure

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Acute scleroderma renal crisis off-label use 236503001
Diastolic heart failure off-label use 418304008 DOID:9775
Hypertension due to Scleroderma off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Intestinal Angioedema contraindication
Head and Neck Angioedema contraindication
Hemodialysis with High-Flux Membrane contraindication
Severe Aortic Valve Stenosis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

ProductApplicantIngredients
Cardalis Ceva Sante Animale 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.9 acidic
pKa2 5.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.70 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.77 CHEMBL

External reference:

IDSource
4020817 VUID
N0000148336 NUI
D00620 KEGG_DRUG
86541-74-4 SECONDARY_CAS_RN
1546196 RXNORM
4020025 VANDF
4020817 VANDF
C0053091 UMLSCUI
CHEBI:3011 CHEBI
CHEBI:88200 CHEBI
CHEMBL838 ChEMBL_ID
CHEMBL1694 ChEMBL_ID
DB00542 DRUGBANK_ID
C044946 MESH_SUPPLEMENTAL_RECORD_UI
5362124 PUBCHEM_CID
6374 IUPHAR_LIGAND_ID
C052133 MESH_SUPPLEMENTAL_RECORD_UI
6375 IUPHAR_LIGAND_ID
6129 INN_ID
UDM7Q7QWP8 UNII
DB14125 DRUGBANK_ID
1267 MMSL
4251 MMSL
48720 MMSL
d00730 MMSL
003597 NDDF
003598 NDDF
108572003 SNOMEDCT_US
108573008 SNOMEDCT_US
372511001 SNOMEDCT_US
C0105523 UMLSCUI
CHEMBL1192519 ChEMBL_ID
6128 INN_ID
86541-78-8 SECONDARY_CAS_RN
5463984 PUBCHEM_CID
JRM708L703 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 31 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0228 TABLET 20 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0229 TABLET 20 mg ORAL NDA authorized generic 23 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-554 TABLET 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-561 TABLET, FILM COATED 40 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-566 TABLET 10 mg ORAL ANDA 13 sections
BENAZEPRIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-259 TABLET 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-280 TABLET 10 mg ORAL ANDA 12 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-327 TABLET, FILM COATED 20 mg ORAL ANDA 19 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-612 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections